Developments in the pharmacological treatment of schizophrenia (Q34974846)

5 August 2017

1 reference

title

Developments in the pharmacological treatment of schizophrenia (English)

1 reference

5 August 2017

0 references

Robin Murray

0 references

Gina Kuperberg

1 reference

5 August 2017

Robert Kerwin

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Expert Opinion on Investigational Drugs

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

1335-1341

1 reference

Compliance therapy in psychotic patients: randomised controlled trial

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Treatment of negative symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Longitudinal assessment of premorbid cognitive functioning in patients with schizophrenia through examination of standardized scholastic test performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Generalized cognitive deficits in schizophrenia: a study of first-episode patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Dopamine receptor pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Failure to find linkage between a functional polymorphism in the dopamine D4 receptor gene and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

No difference in the expression of the D4 gene in post-mortem frontal cortex from controls and schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

3-((4-(4-Chlorophenyl)piperazin-1-yl)-methyl)-1H-pyrrolo-2,3-b-pyridine: an antagonist with high affinity and selectivity for the human dopamine D4 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Decreased prefrontal dopamine D1 receptors in schizophrenia revealed by PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

(-)-Stepholidine: a potential novel antipsychotic drug with dual D1 receptor agonist and D2 receptor antagonist actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

The emerging role of glutamate in the pathophysiology and treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Striatal dopamine D2-receptor blockade by typical and atypical neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Clozapine, single photon emission tomography, and the D2 dopamine receptor blockade hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Clozapine-induced agranulocytosis. A genetic and epidemiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Clozapine: efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

An open comparison of clozapine and risperidone in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Transient versus sustained visual channels in the visual backward masking deficits of schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Seroquel: biochemical profile of a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Ziprasidone: a new atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Neurobehavioral Deficits at Adolescence in Children at Risk for Schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

Dopamine D3 receptor gene polymorphism and response to clozapine in schizophrenic Pakistani patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.11.10.1335

10.1517/13543784.11.10.1335

21 January 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference